SASL Swiss Cirrhosis Cohort
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Oct 17, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The SASL Swiss Cirrhosis Cohort study is a national research project that aims to better understand liver cirrhosis, a serious condition where the liver becomes damaged and scarred. This study will follow patients with cirrhosis over time to collect important information about their health, treatments, and quality of life. Researchers will also gather biological samples, like blood, to help answer specific medical questions that arise from the data they collect.
To participate in this study, you must be between 65 and 74 years old and have a confirmed diagnosis of cirrhosis. There is also an opportunity for healthy individuals without cirrhosis to join as control subjects. Participants will be monitored regularly, and they can help advance research that may lead to better treatments for liver cirrhosis in the future. Importantly, individuals under 18 or those with certain types of liver cancer are not eligible to participate. This study is currently recruiting participants, and your involvement could make a significant difference in understanding this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A) Patients with chronic liver disease and histologically proven cirrhosis
- • B) Control subjects with no signs of cirrhosis
- Exclusion Criteria:
- • Age \<18 years
- • patients who developed hepatocellular carcinoma (HCC) and/or cholangiocellular carcinoma (CCC)
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lugano, Ticino, Switzerland
Basel, , Switzerland
Bern, , Switzerland
Geneva, , Switzerland
Lausanne, , Switzerland
Lugano, , Switzerland
Saint Gallen, , Switzerland
Zurich, , Switzerland
Zurich, , Switzerland
Zurich, , Switzerland
Basel, , Switzerland
Patients applied
Trial Officials
Christine Bernsmeier, Prof. Dr. med.
Principal Investigator
University Centre for Gastrointestinal and Liver Diseases, University Hospital Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported